This article is more than 5 years old. Information may no longer be current.

ASCRS task force to investigate CyPass micro-stent study data

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American Society of Cataract and Refractive Surgery will form a task force to review the COMPASS-XT study data that recently led to a voluntary recall of Alcon’s CyPass micro-stent.

ASCRS Clinical Committee leaders who specialize in glaucoma and cornea will make up the task force, which will conduct an independent evaluation of the data, according to a press release.

“ASCRS takes seriously its responsibility to empower its members to provide the absolute best surgical care,” ASCRS President Thomas W. Samuelson, MD, said in the release. “With clinical committees in both glaucoma and cornea, each comprised of nationally recognized experts, ASCRS is uniquely suited to provide independent analysis and guidance concerning the clinical implications of the CyPass withdraw. As the leading U.S. society principally dedicated to meeting the needs of anterior segment surgeons and their patients, we believe it is our responsibility to serve in this capacity.”

Alcon voluntarily recalled all CyPass micro-stent devices after 2-year data of the COMPASS study found a statistically significant difference in endothelial cell loss at 5 years after surgery in patients who received the device compared to those who underwent cataract surgery alone.